The ergonomic syringe features cushioned grips and 100% recyclable packaging, approved for use in EU, US, and Canada.
Galderma has received regulatory approval in the European Union, United States, and Canada for a new syringe designed for use with its NASHA lidocaine range of Restylane products across multiple facial and hand indications.
The next-generation syringe features an ergonomic design with a cushioned finger grip and thumb rest, developed in collaboration with more than 70 aesthetic practitioners to improve injection comfort and control. The device includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance needle and color-coded packaging to support easy range navigation.
“Developing this new syringe in close collaboration with practitioners to address their specific needs has really set it apart. Repetitive hand movements like performing numerous injections every day can lead to strain and reduced mobility, but the syringe’s ergonomic design, with a cushioned finger grip and thumb rest ensure maximum comfort when injecting, supporting consistent, high-quality results for patients,” says Dr Luddi Luiz Oliveira, plastic surgeon in Brazil, in a release.
Sustainability Focus in Packaging Design
The syringe’s carton packaging represents the first in the injectable aesthetics industry made from 100% recyclable paper, according to a release from Galderma, which notes that the compact paper-only design reduces in-clinic waste by up to 30% based on volume reduction compared to previous packaging.
The device was optimized for ergonomic functionality, ease of aspiration, ease of operation, and premium appearance through direct practitioner feedback during development.
Approved Product Range
The new syringe is approved for use with NASHA lidocaine range products including Restylane Lyft Lidocaine, Restylane Eyelight, and Restylane-L (known as Classyc Lidocaine in some markets). Approved indications include multiple facial areas such as cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, and hands.
“This next-generation syringe reflects the latest advancements in injection design, giving aesthetic practitioners greater precision, improved ergonomics, and enhanced control. By refining every element of the injector experience, we aim to help clinicians deliver consistently premium results for their patients,” says Baldo Scassellati Sforzolini, MD, PhD, global head of research and development at Galderma, in a release.
Galderma’s Restylane portfolio offers four hyaluronic acid technologies: NASHA, NASHA HD, OBT, and SB-NASHA, ranging from firmer gels for contouring and structural support to soft, flexible formulations for smoothing facial lines and wrinkles. The company reports more than 77 million Restylane treatments have been administered worldwide over 30 years of use.
ID 230170984 © Irina Ivanova | Dreamstime.com
